Continuous Manufacturing Line for Oral Solids, WuXi STA, China
WuXi STA, a subsidiary of WuXi AppTec, opened the doors of its first pharmaceutical product Continuous Manufacturing (CM) line for oral solids at the drug product site located in Wuxi city, China in January 2023. This new CM line provides global customers with an enhanced oral drug development solution, enabling higher yields and shortened timelines to market.
WuXi STA’s continuous manufacturing line features continuous direct compression equipment with unit operations including dispensing, blending, lubrication, tablet compression, and coating. The equipment design complies with the global cGMP regulations. Process Analytical Technology (PAT) is implemented within the CM line to monitor blending uniformity, allowing for real-time analysis and control during production to ensure high product quality.
WuXi STA’s drug product facilities across North America, Europe, and Asia have been inspected by major regulatory agencies including US FDA, EMA, China NMPA, SwissMedic, Japan PMDA, and South Korea MFDS to support global customers with clinical and commercial drug product manufacturing services. The Wuxi city site, where this new CM line was launched, is an integrated formulation development and manufacturing campus with a comprehensive analytical platform for both oral and injectable formulations.
Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, commented:
“I am glad that our first oral solid-dose drug product continuous manufacturing line has been launched in the Wuxi city site. As a trusted partner and a global enabler, WuXi STA will continue to build first-class facilities with cutting-edge technologies to make more innovative medicines accessible to patients worldwide.”
About WuXi STA
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations across Asia, North America, and Europe. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.
For more information, please visit: www.STApharma.com
Recommended Companies
Latest Projects
- Merck KGaA Invests € 300m for New Research Centre in Darmstadt, Germany
Merck KGaA (Merck) announced an investment today of more than €300 Million ($320.8m) in a new Life Science Research Centre - Production Facilities Expansion, Novo Nordisk, Chartres, France
Novo Nordisk, a global pharmaceutical leader, has set in motion an extensive expansion project for its production facility in Chartres, - Manufacturing Pharmaceuticals In Space
Varda Space Industries, a California-based startup, is venturing into the realm of pharmaceutical manufacturing in microgravity with the goal of - Plasma-Derived Therapies Manufacturing Plant, 2030, Takeda, Osaka, Japan
Takeda plans to invest approximately 100 Billion Yen ( 762,330,000 Million USD) to construct a new manufacturing plant for plasma-derived - Continuous Manufacturing Line for Oral Solids, WuXi STA, China
WuXi STA, a subsidiary of WuXi AppTec, opened the doors of its first pharmaceutical product Continuous Manufacturing (CM) line for - BioNTech Boosts Autonomy with In-House Plasmid DNA Manufacturing Facility in Marburg
The construction of BioNTech’s first in-house plasmid DNA processing plant in Marburg, Germany, has now been completed, the company announced
